

Baseline Data

The following data shows the ocular baseline data which has been summarised on the eye-level.

Table 1: Ocular baseline data – eye level (all centres)

	Tocilizumab (N=21)
Topical steroid drops	
Not done	0
Missing	1
N	28
Mean (SD)	2.6 (1.4)
Median (IQR)	3 (1, 4)
(Min, Max)	(0, 5)
LogMAR score	
Not done	0
Missing	0
N	29
Mean (SD)	0.1 (0.3)
Median (IQR)	0 (-0.1, 0.2)
(Min, Max)	(-0.1, 1.2)
AC cells (SUN)	
Not done	0
Missing	0
N	29
1+	6 (20.7%)
2+	9 (31%)
3+	11 (37.9%)
4+	3 (10.3%)
Flare score (SUN)	
Not done	0
Missing	0
N	29
0	4 (13.8%)
1+	21 (72.4%)
2+	4 (13.8%)
LOCS III Grading: Pseudophakic	
Not done	0
Missing	0
N	29
No	25 (86.2%)
Yes	4 (13.8%)
LOCS III Grading: Nuclear	
Not done	4
Missing	0

	Tocilizumab (N=21)
N	25
N0	24 (96%)
NI	1 (4%)
LOCS III Grading: Cortical	
Not done	4
Missing	0
N	25
No Cortical Cataract	24 (96%)
CI	1 (4%)
LOCS III Grading: Posterior	
Not done	4
Missing	0
N	25
0	24 (96%)
PI	1 (4%)
Other Structural Changes: Central band-keratopathy – covering visual axis	
Not done	0
Missing	0
N	29
No	28 (96.6%)
Yes	1 (3.4%)
Other Structural Changes: Synchiae	
Not done	0
Missing	0
N	29
No	25 (86.2%)
Yes	4 (13.8%)
Other Structural Changes: Iris bombe	
Not done	0
Missing	0
N	29
No	29 (100%)
Other Structural Changes: Membrane formation	
Not done	0
Missing	0
N	29
No	28 (96.6%)
Yes	1 (3.4%)
Other Structural Changes: Neovascularisation	
Not done	0
Missing	0

	Tocilizumab (N=21)
N	29
No	29 (100%)
Intraocular pressure (IOP)	
Not done	0
Missing	0
N	29
Mean (SD)	13.8 (3.2)
Median (IQR)	13 (12, 16)
(Min, Max)	(8, 21)

Table 2: Ocular baseline data – best eye (all centres)

	Tocilizumab (N=21)
Topical steroid drops	
Not done	0
Missing	1
N	20
Mean (SD)	2.6 (1.5)
Median (IQR)	3 (1, 4)
(Min, Max)	(0, 5)
LogMAR score	
Not done	0
Missing	0
N	21
Mean (SD)	0.1 (0.2)
Median (IQR)	0 (-0.1, 0.2)
(Min, Max)	(-0.1, 0.5)
AC cells (SUN)	
Not done	0
Missing	0
N	21
1+	5 (23.8%)
2+	7 (33.3%)
3+	6 (28.6%)
4+	3 (14.3%)
Flare score (SUN)	
Not done	0
Missing	0
N	21
0	3 (14.3%)
1+	15 (71.4%)
2+	3 (14.3%)

LOCS III Grading: Pseudophakic	
Not done	0
Missing	0
N	21
No	18 (85.7%)
Yes	3 (14.3%)
LOCS III Grading: Nuclear	
Not done	3
Missing	0
N	18
N0	17 (94.4%)
N1	1 (5.6%)
LOCS III Grading: Cortical	
Not done	3
Missing	0
N	18
No Cortical Cataract	18 (100%)
LOCS III Grading: Posterior	
Not done	3
Missing	0
N	18
0	17 (94.4%)
P1	1 (5.6%)
Other Structural Changes: Central band-keratopathy – covering visual axis	
Not done	0
Missing	0
N	21
No	21 (100%)
Other Structural Changes: Synchia	
Not done	0
Missing	0
N	21
No	17 (81%)
Yes	4 (19%)
Other Structural Changes: Iris bombe	
Not done	0
Missing	0
N	21
No	21 (100%)
Other Structural Changes: Membrane formation	
Not done	0
Missing	0
N	21

No	20 (95.2%)
Yes	1 (4.8%)
Other Structural Changes: Neovascularisation	
Not done	0
Missing	0
N	21
No	21 (100%)
Intraocular pressure (IOP)	
Not done	0
Missing	0
N	21
Mean (SD)	13.8 (3.5)
Median (IQR)	13 (11, 16)
(Min, Max)	(8, 21)

Table 3: Ocular baseline data – worst eye (all centres)

	Tocilizumab (N=21)
Topical steroid drops	
Not done	0
Missing	1
N	20
Mean (SD)	2.7 (1.4)
Median (IQR)	3 (1.5, 4)
(Min, Max)	(0, 5)
LogMAR score	
Not done	0
Missing	0
N	21
Mean (SD)	0.2 (0.3)
Median (IQR)	0.1 (0, 0.2)
(Min, Max)	(-0.1, 1.2)
AC cells (SUN)	
Not done	0
Missing	0
N	21
1+	5 (23.8%)
2+	5 (23.8%)
3+	8 (38.1%)
4+	3 (14.3%)
Flare score (SUN)	
Not done	0
Missing	0

	Tocilizumab (N=21)
N	21
0	2 (9.5%)
1+	16 (76.2%)
2+	3 (14.3%)
LOCS III Grading: Pseudophakic	
Not done	0
Missing	0
N	21
No	18 (85.7%)
Yes	3 (14.3%)
LOCS III Grading: Nuclear	
Not done	3
Missing	0
N	18
N0	17 (94.4%)
NI	1 (5.6%)
LOCS III Grading: Cortical	
Not done	3
Missing	0
N	18
No Cortical Cataract	17 (94.4%)
CI	1 (5.6%)
LOCS III Grading: Posterior	
Not done	3
Missing	0
N	18
0	17 (94.4%)
PI	1 (5.6%)
Other Structural Changes: Central band-keratopathy – covering visual axis	
Not done	0
Missing	0
N	21
No	20 (95.2%)
Yes	1 (4.8%)
Other Structural Changes: Synchiae	
Not done	0
Missing	0
N	21
No	17 (81%)
Yes	4 (19%)
Other Structural Changes: Iris bombe	
Not done	0

	Tocilizumab (N=21)
Missing	0
N	21
No	21 (100%)
Other Structural Changes: Membrane formation	
Not done	0
Missing	0
N	21
No	20 (95.2%)
Yes	1 (4.8%)
Other Structural Changes: Neovascularisation	
Not done	0
Missing	0
N	21
No	21 (100%)
Intraocular pressure (IOP)	
Not done	0
Missing	0
N	21
Mean (SD)	14.4 (3)
Median (IQR)	13.5 (12.7, 16.5)
(Min, Max)	(10, 21)

Table 4: Rheumatoid baseline data – Individual Level (all centres)

	Tocilizumab (N=21)
Type of JIA (ILAR classification)	
Not done	0
Missing	0
N	21
Extended oligoarthritis	6 (28.6%)
Persistent oligoarthritis	7 (33.3%)
Polyarthritis RF negative	7 (33.3%)
Psoriatic arthritis	1 (4.8%)
Disease duration (years)	
Not done	0
Missing	0
N	21
Mean (SD)	9 (4.4)
Median (IQR)	9.8 (5, 12.1)
(Min, Max)	(0.5, 15.5)
Physician global assessment of disease activity	
Not done	0
Missing	0
N	21
Mean (SD)	2 (2)
Median (IQR)	1.6 (0.2, 3)
(Min, Max)	(0, 7.5)
Active joint count [all joints]	
Not done	0
Missing	0
N	21
Mean (SD)	0.9 (1.7)
Median (IQR)	0 (0, 1)
(Min, Max)	(0, 6)
Swollen joint count [all joints]	
Not done	0
Missing	0
N	21
Mean (SD)	1.1 (1.9)
Median (IQR)	0 (0, 1)
(Min, Max)	(0, 6)
Anti-nuclear antibody (ANA)	
Not done	1
Missing	0
N	20

	Tocilizumab (N=21)
Negative	5 (25%)
Positive	15 (75%)
Double-stranded deoxyribonucleic acid (DsDNA)	
Not done	0
Missing	0
N	21
Negative	18 (85.7%)
Positive	3 (14.3%)
Extractable nuclear antigen (ENA)	
Not done	4
Missing	0
N	17
Negative	16 (94.1%)
Positive	1 (5.9%)